Study of Prothrombotic Changes in Metabolic Syndrome

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Hematology

Background:

• Metabolic syndrome is a cluster of risk factors including central obesity, often co-occurring with diabetes and cardiovascular diseases.
• Understanding the link between metabolic syndrome and coagulation is crucial for managing associated health risks.

Purpose of the Study:

• To investigate the relationship between coagulation abnormalities and metabolic syndrome.
• To assess specific coagulation markers in individuals with metabolic syndrome compared to controls.

Main Methods:

• A prospective cross-sectional study was conducted with 50 metabolic syndrome cases and 50 matched controls.
• Coagulation parameters including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, Plasminogen Activator Inhibitor 1 (PAI1), and Factor VIII were measured.

Main Results:

• Metabolic syndrome cases exhibited significantly elevated Fibrinogen, Factor VIII, and PAI1 levels.
• Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) were shorter in the metabolic syndrome group.
• Coagulation parameters showed significant correlations with individual components of metabolic syndrome.

Conclusions:

• Metabolic syndrome represents a hypercoagulable state.
• Further research is warranted to explore the consequences of this hypercoagulable state.
• Clinical trials evaluating prophylactic anticoagulation for venous thrombosis prevention in metabolic syndrome patients are recommended.